论文部分内容阅读
本文最初发表于2015年《Leukemia Research》杂志第39卷,题录为:Liu L,Jiao W,Zhang Y,et al.Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor(CAG regimen)compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia[J].Leuk Res,2015,39:323-328。文章表明CAG预激方案对复发/难治性ALL的再诱导缓解效能与Hyper-CVAD方案相仿,且毒副作用少,安全性高;此外,与B淋系复发/难治性ALL相比,CAG预激方案对T淋系复发/难治性ALL的疗效更为突出。该结果为CAG预激方案应用于复发/难治性ALL的再诱导缓解治疗提供了临床实践依据。经通信作者的许可,再次通过佳文解读的方式阐明这一治疗方案,供各位赏析。
This article was first published in volume 39 of the 2015 Leukemia Research magazine, entitled: Liu L, Jiao W, Zhang Y, et al. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen )compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia [J]. Leuk Res, 2015, 39:323-328. The article shows that the effect of CAG priming regimen on re-induction and remission of relapsed/refractory ALL is similar to that of Hyper-CVAD regimen, with fewer side effects and high safety; in addition, CAG is compared with recurrent/refractory ALL in B lymphoid system. The prepulse regimen is more effective for T-lymphatic relapse/refractory ALL. This result provides a clinical practice basis for the CAG prepulse regimen to be used for the re-induction remission therapy of relapsed/refractory ALL. With the permission of the author of the communication, this treatment plan was clarified again through the interpretation of Jiawen, for everyone to appreciate.